Xiao-Jun Ma @ 2024 Biomarkers of Aging Conference

Xiao-Jun Ma highlights the innovative NULISA technology developed by Alamar Biosciences and its applications in key partnerships, including collaboration with the Biomarkers of Aging Consortium.
Timestamps
[00:00:40] NULISA: NUcleic acid-Linked Immuno-Sandwhich Assay: highly sensitive immunoassays for multiplexed protein detection
[00:03:27] NULISAseq: Inflammation Panel 250: the most complete coverage of cytokines and chemokines on the market
[00:04:37] NULISAseq: CNS Disease Panel 120
[00:05:36] How Alamar Bio supports collaboration with the Biomarkers of Aging Consortium to identify and validate biomarkers of aging for longevity interventions
[00:08:30] Summary
Xiao-Jun Ma, CTO of Alamar Biosciences, leads the development of cutting-edge proteomics technology for highly sensitive protein biomarker detection. Alamar Biosciences is a key partner of the Biomarkers of Aging Consortium, contributing to its Challenge and other programs. Learn more at alamarbio.com.